Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12
Background
The varicella-zoster virus (VZV), belonging to the group of human α-herpesviruses, has yet to be developed as a platform for oncolytic virotherapy, despite indications from clinical case reports suggesting a potential association betw…